1 2 3 4	Reevaluation of Seroprevalence using a Semi-quantitative Anti-spike IgG in Health Care workers at an Academic Medical Center in Boston, Massachusetts
5 6 7 8	Manisha Cole ^{1,2} , Elizabeth R. Duffy ² , Jordyn N Osterland ^{1,2} , Susan Gawel ³ , Lei Ye ³ , Kyle de la Cena ² , Elizabeth J. Ragan ⁴ , Sarah E. Weber ⁴ , Elissa M- Schechter- Perkins ⁵ , Tara C. Bouton ⁴ , Karen R. Jacobson ⁴ , Chris Andry ^{1,2} , Yachana Kataria ^{1,2*}
9 10 11 12 13 14 15 16	 ¹Department of Pathology and Laboratory Medicine, Boston Medical Center, Boston, MA ²Department of Pathology and Laboratory Medicine, Boston University School of Medicine, Boston, MA ³Abbott Laboratories, Department of Biostatistics ⁴Section of Infectious Diseases, Boston Medical Center, Boston, MA ⁵Department of Emergency Medicine, Boston University School of Medicine / Boston Medical Center, Boston, MA
17 18	Running Title: SARS-CoV-2 IgG Semi-Quantitative Assay
19 20 21	Conflict-of-interest disclosure The authors declare no competing financial interests.
22 23 24 25 26 27 28 29 30 31 32 33 34	Corresponding Author Yachana Kataria, PhD, DABCC Medical Director, Clinical Chemistry Department of Pathology and Lab Medicine 670 Albany St. Boston, MA 02118 Tel: 617-414-3727 Email: <u>Yachana.Kataria@bmc.org</u> Abstract (250 words)
35	
36	Background: Accurate measurement of antibodies is a necessary tool for assessing exposure
37	to SARS-CoV-2 and facilitating understanding of the role of antibodies in immunity. Most assays
38	are qualitative in nature and employ a threshold to determine presence of antibodies. Semi-
39	quantitative assays are now available. Here we evaluate the semi-quantitative SARS-CoV-2 IgG
40	II (anti-spike (S)) assay. We aim to reassess the seroprevalence using anti- S assay and
41	subsequently compare it to the previously measured IgG (anti-nucleoprotein (N)) in health care
42	workers at an academic medical center in Boston.

Λ	3
-	<u> </u>

44	Methods: 1743 serum samples from HCWs at Boston Medical Center were analyzed for SARS-
45	CoV-2 anti-S IgG and IgM using the Abbott SARS-CoV-2 IgG II and Abbott AdviseDx SARS-
46	CoV-2 IgM assay, respectively. Precision, linearity, positive and negative concordance with prior
47	RT-PCR test were evaluated for anti-S IgG. Seroprevalence and its association with
48	demographics variables was also assessed.
49	
50	Results: Linearity and precision results were clinically acceptable. The positive and negative
51	concordance for anti-S IgG with RT-PCR was 88.2% (95% CI: 79.4% - 94.2%) and 97.43%
52	(95% CI: 95.2% - 98.8%), respectively. Overall, 126 (7.2%) of 1,743 participants were positive
53	by anti-S IgG. Among the 1302 participants with no prior RT-PCR, 40 (3.1%) were positive for
54	anti-S IgG antibody. The original agreement in this population with the qualitative, anti-N IgG
55	assay was 70.6%. Upon optimizing the threshold from 1.4 to 0.49 S/CO of the anti-N IgG assay,
56	the positive agreement of the assay increases to 84.7%.
57	
58	Conclusion: The anti-S IgG assay demonstrated reproducible and reliable measurements. This
59	study highlights the presence of asymptomatic transmission among individuals with no prior
60	history of positive RT-PCR. It also highlights the need for optimizing thresholds of the qualitative
61	SARS-CoV-2 IgG assay for better agreement between assays by the same vendor.
62	
63	
64	
65	
66	
67	
68	
	45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 61 62 63 64 65 66 67

69 Introduction

70 Coronavirus disease 2019 (COVID-19) is the disease caused by the novel severe acute 71 respiratory syndrome coronavirus 2 (SARS-CoV-2) that causes fever, cough, shortness of 72 breath, and fatigue that can guickly become life threatening (1-3). SARS-CoV-2 RNA testing 73 alone, in the absence of serological testing, is not sufficient to assess population-level viral 74 transmission and pathogen exposure and the public health burden of the pandemic (4). The 75 transient nature of RNA testing makes it an inaccurate metric to assess viral transmission at a 76 population level. Accurate measurement of antibodies can facilitate understanding the role of 77 antibodies in immunity elicited by both natural and vaccine response (5, 6). Ongoing studies are 78 investigating the durability of antibodies against SARS-CoV-2 and examining what levels confer 79 protective immunity against severe disease and/or reinfection (6-9).

80

81 There has been a rapid increase in serological assay availability in the United States via 82 Emergency Use Authorization (EUA) from the Food and Drug Administration (FDA)(4, 10). 83 These assays are designed to detect different immunoglobulin classes (IgM, IgG, IgA) or total 84 antibodies to various epitopes of SARS-CoV-2. SAR-CoV-2 epitopes include the spike (S) or 85 nucleocapsid (N) proteins. Most currently approved assays are qualitative in nature and employ 86 a threshold to determine the presence of antibodies. Semi-guantitative assays are now 87 available. To date, there are over 15 semi-quantitative assays approved for clinical testing in the 88 United States including Roche Elecsys Anti-SARS-CoV-2 S, Phadia, Beckman Coulter, Inc. 89 Access SARS-CoV-2 IgG II, AB EliA SARS-CoV-2-Sp1 IgG Test Phadia, Dimension EXL 90 SARSCoV2 IgG, and Quanterix Simoa Semi-Quantitative SARS-CoV-2 IgG Antibody Test 91 among others (11). However, it remains unclear if the pre-defined threshold for current 92 qualitative and semi-quantitative assays is appropriately set (4, 12). It is also unclear whether 93 these SARS-CoV-2 serological assays are comparable which prohibits assessment of durability 94 and correlation with protection to help inform public health policies (4, 13).

95

- 96 We previously assessed seroprevalence among health care workers at an
- 97 (11)(11)(11)academic medical center in Boston, Massachusetts, USA using the qualitative
- 98 assay SARS-CoV-2 IgG (anti-nucleoprotein (N)) assay (11). Seroprevalence studies can assist
- 99 in detecting asymptomatic and symptomatic infection and provide a cumulative prevalence
- 100 estimate. Abbott Laboratories has now been issued an EUA for its anti-spike quantitative SARS-
- 101 CoV-2 IgG II (anti-S IgG) and IgM (anti-S IgM) assay (6). In this study, we aim to reevaluate the
- 102 seroprevalence in health care worker (HCW) population using the anti-S IgG assay and
- 103 compare it to the anti-N IgG assay.

104

105

106

108 Methods

109 **Study Design & Participants**

- 110 Baseline samples were obtained from an ongoing longitudinal cohort assessing COVID-19
- serological status among HCW's at Boston Medical Center (BMC). In brief, participants were
- adult BMC employees who worked on campus during the first COVID-19 surge in Boston, MA
- 113 (March 13th-May 31st, 2020). Baseline serum samples were obtained between July 13th-26th,
- 114 2020 (n= 1,743) and had been previously analyzed for anti-N IgG antibody status (Abbott
- 115 Laboratories, Abbott Park, IL). Participants completed extensive questionnaire data on
- demographics (age, gender, race, ethnicity) between January 1st My 31st, 2020. Prior RT-
- 117 PCR COVID-19 test results completed at BMC during the same period, were confirmed in
- 118 the electronic medical record. This project was approved by the Institutional Review Board at
- 119 Boston University Medical Center (BUMC).
- 120
- For the current investigation, we analyzed serum samples for SARS-CoV-2 anti-S IgG & IgM (n = 1,743). These assays were performed by the clinical pathology laboratory at BMC on the
- 122 = 1,740). These assays were performed by the official pathology labelatory at Dive of the
- 123 Abbott Architect i2000 Instrument (Abbott Laboratories, Abbott Park, IL). Assays were run per
- 124 the manufacturer's instructions. For both assays, aliquots of serum samples (~500 ul) were
- 125 thawed for either 24 hours at 4°C or 2 hours at room temperature prior to being analyzed.
- 126
- 127
- 128

129 SARS-CoV-2 IgM Assay (Qualitative)

130 The AdviseDx SARS-CoV-2 IgM (anti-S IgM) assay is a chemiluminescent microparticle

131 immunoassay (CMIA) for the qualitative detection of IgM antibody in human serum against the

- 132 SARS-CoV-2 spike protein.
- 133

134	In this automated assays, participant serum, paramagnetic particles coated with SARS-CoV-2
135	antigen, and an assay diluent are incubated together during which the antibodies present in the
136	serum sample bind to the antigen. The resulting luminescence will be read and resulted as a
137	relative light unit (RLU). Both assays rely on an assay-specific calibrator to report a ratio of
138	specimen RLU to calibrator RLU. Interpretation of positivity is determined by an index
139	value above a predefined threshold (8, 9).
140	
141	IgM samples were interpreted as positive (index value \ge 1.00) or negative (index value < 1.00).
142	Both qualitative and quantitative results were used in the analysis.
143	
144	Anti-S IgG Assay (Semi-Quantitative)
145	Aliquots of serum samples (~500 ul) were thawed for either 24 hours at 4°C or 2 hours at room
146	temperature prior to being analyzed.
147	
148	The Abbott ARCHITECT SARS-CoV-2 IgG II assay is a semi-quantitative assay that detects
149	IgG antibodies to the receptor binding domain (RBD) of the S1 subunit of the spike protein of
150	SARS-CoV-2 in human plasma. It is a two-step indirect CMIA.
151	
152	The assay utilizes magnetic microparticles coated with RBD recombinant protein. The mixture is
153	incubated and then washed prior to the addition of an anti-human-IgG antibody conjugated to
154	acridinium. The recorder molecule is incubated prior to a second wash and followed by addition
155	of a triggering solution that generates luminescence. The light is captured and counted to give
156	an RLU. The RLU's are read of a six-point calibration curve stored on the instrument generating
157	an AU/mL (arbitrary units/milliliter) value. The assay is standardized to a monoclonal antibody
158	concentration (14). Samples were interpreted as positive when >= 50.0 AU/mL or negative
159	when <50.0 AU/mL. Both qualitative and quantitative results were used in the analysis.

160

161 Precision SARS-CoV-2 IgM & Anti-S IgG

- 162 Precision studies were performed on quality control (QC) material as supplied by Abbott
- 163 Diagnostics. IgM has two levels of QC: negative and positive. Anti-S IgG has three levels of QC:
- negative, low positive, and high positive. Intra-day precision was assessed by analyzing 20
- 165 replicates of each level of QC on the same day. Inter-day precision was assessed by analyzing

166 QC for 20 days.

167

168 Linearity Anti-S IgG Studies

169 The analytical measuring range of anti-S IgG is 22.0 - 25,000 AU/mL. The suggested

170 manufacturer dilution is 1:2, extending the measuring upper limit to 50,000 AU/mL.

171 Dilution studies were carried out using two participants that had elevated serum samples.

172 Although the EUA approved upper linearity is 25,000 AU/mL, reagent was received prior to EUA

approval and was reported to be 50,000 AU/mL at the time of these analyses. These samples

were diluted serially with negative control. A total of 7 levels were tested in triplicates on the

175 Abbott Architect i2000 instrument.

176

177 Statistical Analysis

178 Questionnaire data were collected and managed in REDCap electronic data capture tools

179 hosted at Boston University, CTSI 1UL1TR001430 (15, 16). Imprecision was assessed by

180 measuring mean, standard deviation (SD), and coefficient of variation (CV) for inter and intra-

181 day precision. Anti-S IgG data were log transformed (base 2) for analysis and ease of

182 visualization.

184	Categorical data are presented as counts. We tested the association between anti-S IgG with
185	sex, race, and gender using a Fisher's Exact Test analysis. Missing data of less than 5% was
186	excluded from analysis.
187	
188	Positive and negative concordance of anti-S IgG was calculated using molecular testing (RT-
189	PCR) as the gold standard among participants with a prior RT-PCR test result. Comparison
190	between assays was assessed by Mcnemar's chi-squared test. Receiver operating
191	characteristics (ROC) curve was used to assess assay thresholds and define trade-offs in assay
192	sensitivity and specificity using to RT-PCR test as the gold standard.
193	
194	A P-value of < 0.05 was considered statistically significant, and all tests were two-sided.
195	Analyses were performed in R Version R-3.5.3 (R Foundation for Statistical Computing). Select
196	figures were produced by GraphPad Prism version (9.0.2) by GraphPad Software (San Diego,
197	USA).
198	
199	Results
200	
201	Precision
202	IgM negative and positive control exhibited an intra-day CV of 16.5%, and 2.2%, respectively.
203	IgM negative and positive control exhibited an inter-day CV of 21.3%, and 1.9%, respectively
204	(Supplementary Table 1).
205	
206	Anti-S IgG negative, low positive, and high positive control exhibited an intra-day CV of 23.9%,
207	3.3%, and 2.9%, respectively. Anti-S IgG negative, low positive, and high
208	positive control exhibited an inter-day CV of 16.6%, 2.4%, and 2.4%, respectively

209 (Supplementary Table 1).

210

211 Anti-S IgG Linearity

- Linearity data is shown in Figure 1. Figure 1a displays a participant result with greater than the
- analytical measuring range (46,820 AU/mL) and shows an acceptable linear response with a r-
- squared value of 0.99. Similarly, Figure 1b displays a participant result that had an original anti-
- S IgG level of 11,711.60 AU/mL with acceptable linearity with a r-squared value of 0.99, though
- 216 not at the upper end of the analytical measuring range.
- 217
- 218 **Figure 1 –** Linearity of Anti-S IgG
- 219
- 220 The data suggests that the difference between expected and measured is within the 95% CI.

221 Significant percentage differences are observed on the lower end of the analytical measuring

- 222 range (Supplementary Figure 1).
- 223

224 Seroprevalence

Table 1 shows demographics in relation to anti-S IgG status (n = 1,743). Overall, 126 of 1,743

226 (7.23%) participants were anti-S IgG positive. Participants who were female, Hispanic, or Black

were more likely to be seropositive, but these findings did not reach statistical significance.

228 Obese participants were two times more likely to be seropositive for anti-S IgG [RR: 2.04 (95%

229 CI: 1.40, 2.99)]. Among all the participants, anti-S IgG levels were not associated with age, race,

- 230 or gender (Figure 2a-c).
- 231
- Figure 2 Anti-S IgG by demographics a). Age b). Gender c). Race
- 233
- 441 of 1743 participants had a history of RT-PCR test. 47 of 85 RT-PCR
- 235 confirmed positive individuals were also seropositive by IgM corresponding to a positive
- 236 concordance of 55.3% (95% CI: 44.1% 66.1%). 343 of 350 RT-PCR confirmed

237	negative participants were seronegative by IgM corresponding to a negative concordance of
238	98.0% (95% CI: 95.9% - 99.2%) (Supplementary Table 2). Of the remaining six participants
239	with indeterminate RT-PCR results, two had detectable IgM antibody.
240	
241	75 of the 85 RT-PCR confirmed positive participants were also seropositive by anti-S IgG
242	corresponding to a positive concordance of 88.2% (95% CI: 79.4% - 94.2%). 341 of 350 RT-
243	PCR confirmed negative participants were seronegative by anti-S IgG corresponding to a
244	negative concordance of 97.43% (95% CI: 95.2% - 98.8%) (Table 2). A total of 1302
245	participants had no prior RT-PCR test and of these participants, 40 (3.1%) were positive by anti-
246	S IgG. Distribution of the anti-S IgG levels by RT-PCR test result is shown in Figure 3. Among
247	the individuals with a prior RT-PCR, there is a statistically significant difference among the anti-
248	S IgG levels by RT-PCR test result (p<0.001).
249 250 251	Figure 3 – Anti-S IgG distribution by SARS-CoV-2 RT-PCR status
252	A total of 270 of the 441 individuals with a prior RT-PCR test had a recorded date of RT-PCR.
253	Figure 4 displays anti-S IgG level distribution since RT-PCR date. There was no statistical
254	difference between anti-S levels in individuals less than 120 days after positive RT-PCR test
255	result (p=0.16) (Supplementary Figure 2). Anti-S IgG antibodies in RT-PCR confirmed
256	individuals remained elevated over 120 days post infection.
257	Figure 4 – Anti-S IgG distribution days post SARS-CoV-2 RT-PCR result
	rigure 4 - Anti-Sigo distribution days post SANS-COV-2 INT-FOR result
258	
259	Agreement between Anti-N IgG vs. Anti-S IgG Status
260	Overall agreement between the two assays in this population was found to be 97.5% (95% CI:

96.7% - 98.2%). Of note, the positive agreement was 70.6% (95% CI: 61.8% - 78.4%), whereas

261

- 262 the negative agreement was 99.6% (95% CI: 99.2% - 99.9%). These two tests were found to be 263 statistically different (p<0.001). 264 265 A total of 37 participants had detectable anti-S IgG but were negative by anti-N IgG (Table 266 **3a).** Of these, 11 participants had a positive RT-PCR, 3 participants had a negative RT-PCR, 267 1 participant had an indeterminate RT-PCR, and 22 were not tested. Of interest, 6 participants 268 had detectable anti-N IgG results but were negative by anti-S IgG. 269 Table 3 – Anti-N IgG vs. Anti-S IgG Agreement 270 271 Assay Threshold Optimization 272 ROC curve analysis showed that the SARS-CoV-2 IgG gualitative had optimal sensitivity and 273 specificity target e.g., adjusting threshold to 0.49 S/CO would result in a sensitivity of 84.7% and 274 specificity of at least 96.9% (Supplementary Figure 3). 275 276 As such, changing the threshold of positivity for the anti-N IgG assay from 1.4 to 0.49 S/CO ratio 277 increased the positive agreement between anti-N IgG & anti-S IgG from 70.6% to 86.5% (95% 278 CI: 79.3% - 91.9%). However, it did not appreciably affect the negative agreement, from 99.6%
- to 98.7% (95% CI: 98.0% 99.2%) (**Table 3b)**. Upon threshold modification, the two anti-N IgG
- $280\,$ $\,$ vs. anti-S IgG were found to be statistically aligned.
- 281
- 282

283 **Discussion**

284

- This study reevaluates the seroprevalence in HCWs using a semi-quantitative anti-S IgG assay.
- 286 It also compares the findings to the anti-N IgG in the same population. We report an overall

seroprevalence of 7.2%. Among participants with a negative RT-PCR 2.5% of participants had detectable anti-S IgG antibody. We also observed a seroprevalence of 3.1% among participants with no prior RT-PCR. Our results demonstrate that the anti-S & anti-N IgG assays were statistically different. Upon lowering the anti-N IgG assay threshold, overall agreement between the two assays improved. Taken together, these results support the clinical utility of anti-S IgG assay and highlight the presence of COVID-19 infection among individuals with a negative or no prior RT-PCR.

294

The anti-S IgG shows acceptable intra- and inter-day precision. The precision for the negative control is expected to be high due to a lower numerical value and small variations observed artificially increase the CV. Our results depict acceptable linearity up to 50,000 AU/mL which exceeds upper limit stated in the package insert. It is currently unclear what titer levels confer SARS-CoV-2 immunity but our data suggest that such elevated levels are not rare among the participants.

301

Our results indicate less than ideal positive concordance for anti-S IgG vs. RT-PCR testing which is inconsistent with the manufacturer claims. Further investigation of the discordant samples (n=10) unveil that these participants did not have detectable anti-N IgG, or IgM antibody. These findings can possibly be explained by mild symptoms and/or disease. Literature suggests that the intensity and longevity of antibody response is associated with disease severity (17-19). The negative concordance of the SARS-CoV-2 assay was robust and consistent with the manufacturer claims.

309

Neither SARS-CoV-2 anti-N nor anti-S IgG assays find an association with sex, race, smoking
status. However, the seroprevalence determined by anti-S IgG assay was higher (7.2%) relative
to the anti-N IgG assay (5.5%) (8). The observed seroprevalence at a regional Boston area

313 hospital was comparable to ours (20). Whereas others in the larger Boston region have reported 314 a seroprevalence range between 14% to 25% (21). Seroprevalence can vary between sampling 315 times and geographic regions. Among participants that had no prior RT-PCR test, 40 316 participants had detectable anti-S IgG antibody and 23 participants had detectable anti-N IgG 317 antibody. As such, 17 additional individuals were identified to have IgG antibodies. This 318 suggests higher sensitivity of the anti-S IgG assay which is corroborated by others (22). 319 Alternatively, it may be attributable to a shorter half-life of anti-N IgG antibody (7). 320 321 These individuals pose a risk of asymptomatic viral transmission. Studies suggest that 322 asymptomatic individuals are a source of transmission even after being vaccinated (23-25). 323 Ultimately, RT-PCR testing is limited by the brief infectious window during which viral detection 324 is possible. Detectable viral loads during infection via RT-PCR can vary by several factors such 325 as patient medical history, immune response, and medications, whereas antibody 326 measurements can detect exposure to virus for longer periods of time (26, 27). Our data 327 suggests that participants in the study had elevated anti-S IgG for at least 120 days after RT-328 PCR tests. The longevity of detectable antibody remains unclear especially in less severe 329 infections. 330

331 The gualitative nature of the anti-N IgG assay enabled us to optimize the pre-set threshold. 332 Upon changing the anti-N IgG threshold, the assays exhibit better agreement with anti-S IgG. 20 333 of the 37 discordant participant samples became concordant. The remainder (14/17) discordant 334 participants did not have a prior RT-PCR test, or a robust anti-N IgG response and most also 335 (12/17) had a negative IgM. This suggests either a false positive anti-S IgG result or early 336 detection of the seroconversion process in asymptomatic individuals. We have been following 337 part of this cohort longitudinally and aim to determine if these individuals mount a permanent 338 immune response over time. Furthermore, a study conducted by Public Health England also

independently suggested the same optimized threshold to increase the sensitivity of the assay
(28). Of interest, the same cut-off is currently used in Europe and provides external validation of
our findings. Taken together, our data lend further support for optimizing the assay threshold to
achieve better performance characteristics.

343

These differences between serological assays are also observed between vendors as well. In a head-to-head comparison of five semi-quantitative SARS-CoV-2 IgG assays found that the results from assays are not interchangeable despite good correlation to neutralizing antibody for some of them (10). This has been supported by others (9, 29, 30). Collectively, this highlights the need for harmonization between all serological assays. This is of paramount importance as it will enable us to draw meaningful conclusions about correlation of immunity and being better equipped to overcoming the SARS-CoV-2 pandemic.

351

352 The present study benefited from a large sample size. Certain limitations are acknowledged. 353 The gold standard for determining protective antibody is a virus neutralization test which we 354 were unable to compare to the anti-N & anti-S assay as it requires live pathogen and a biosafety 355 level 3 laboratory. The study is limited by a cross sectional study design which may under- or 356 overestimate the seroprevalence. We were unable to correlate days since RT-PCR result or 357 viral load with quantitative antibody levels and it may provide insight about antibody kinetics 358 (31). The samples were obtained from a single timepoint preventing characterization of antibody 359 kinetics on performance characteristics; however, a subset of participants is being prospectively 360 followed in three-month intervals which will enable future analysis. Lastly, the findings are not 361 generalizable to the larger community and is limited to hospitals.

362

In conclusion, the Abbott SARS-CoV-2 anti-S IgG assay demonstrate acceptable performance
 characteristics. The study highlights the presence of infection among participants with no RT-

365	PCR testing and among those with a negative RT-PCR test. It also highlights the need for
366	optimizing thresholds of the qualitative SARS-CoV-2 IgG assay for better agreement between
367	assays by the same vendor. Serological testing can aid in identify a better assessment of the
368	public health burden.
369	
370	
371	
372	
373	
374	
375	
376	
377	
378	
379	
380	
381	
382	
383	
384	
385	
386	
387 388 389	

200	0	C11 4
390	1:00	oflicts
190	1.01	

391 Abbott Diagnostics provided the reagents for the SARS-CoV-2 IgG II assays.

- 393 Acknowledgements
- 394 We would like to acknowledge the clinical chemistry, phlebotomy, and central receiving staff in
- 395 the Department of Laboratory Medicine and Pathology at Boston Medical Center for working
- 396 with the research team to accomplish this study.
- 398 Funding
- 399 The study was funded, in part, by BMC Development Philanthropy Funds for COVID-19
- 400 research. Abbott Diagnostics provided the reagents for the SARS-CoV-2 IgG II assays.

414 References

415	1. Symptoms 2020 [Available from: <u>https://www.cdc.gov/coronavirus/2019-</u>
416	ncov/symptoms-testing/symptoms.html.
417	2. Wiersinga WJ, Rhodes A, Cheng AC, Peacock SJ, Prescott HC. Pathophysiology,
418	Transmission, Diagnosis, and Treatment of Coronavirus Disease 2019 (COVID-19): A Review.
419	JAMA. 2020;324(8):782-93.
420	3. Asselah T, Durantel D, Pasmant E, Lau G, Schinazi RF. COVID-19: Discovery, diagnostics
421	and drug development. J Hepatol. 2021;74(1):168-84.
422	4. National S-C-SAEG. Performance characteristics of five immunoassays for SARS-CoV-2: a
423	head-to-head benchmark comparison. Lancet Infect Dis. 2020;20(12):1390-400.
424	5. Coste AT, Jaton K, Papadimitriou-Olivgeris M, Greub G, Croxatto A. Comparison of SARS-
425	CoV-2 serological tests with different antigen targets. J Clin Virol. 2021;134:104690.
426	6. Perkmann T, Perkmann-Nagele N, Koller T, Mucher P, Radakovics A, Marculescu R, et al.
427	Anti-Spike Protein Assays to Determine SARS-CoV-2 Antibody Levels: a Head-to-Head
428	Comparison of Five Quantitative Assays. Microbiol Spectr. 2021:e0024721.
429	7. Van Elslande J, Gruwier L, Godderis L, Vermeersch P. Estimated half-life of SARS-CoV-2
430	anti-spike antibodies more than double the half-life of anti-nucleocapsid antibodies in
431	healthcare workers. Clin Infect Dis. 2021.
432	8. Kataria Y, Cole M, Duffy E, de la Cena K, Schechter-Perkins EM, Bouton TC, et al.
433	Seroprevalence of SARS-CoV-2 IgG antibodies and risk factors in health care workers at an
434	academic medical center in Boston, Massachusetts. Sci Rep. 2021;11(1):9694.
435	9. Bradley BT, Bryan A, Fink SL, Goecker EA, Roychoudhury P, Huang ML, et al. Anti-SARS-
436	CoV-2 Antibody Levels Measured by the AdviseDx SARS-CoV-2 Assay Are Concordant with
437	Previously Available Serologic Assays but Are Not Fully Predictive of Sterilizing Immunity. J Clin
438	Microbiol. 2021;59(9):e0098921.
439	10. Perkmann T, Perkmann-Nagele N, Koller T, Mucher P, Radakovics A, Marculescu R, et al.
440	Anti-Spike protein assays to determine post-vaccination antibody levels: a head-to-head
441	comparison of five quantitative assays. medRxiv. 2021:2021.03.05.21252977.
442	11. EUA Authorized Serology Test Performance: Food and Drug Administration; 2021
443	[Available from: https://www.fda.gov/medical-devices/coronavirus-disease-2019-covid-19-
444	emergency-use-authorizations-medical-devices/eua-authorized-serology-test-performance.
445	12. Eyre DW, Lumley SF, O'Donnell D, Stoesser NE, Matthews PC, Howarth A, et al. Stringent
446	thresholds in SARS-CoV-2 IgG assays lead to under-detection of mild infections. BMC Infect Dis.
447	2021;21(1):187.
448	13. Jaaskelainen AJ, Kuivanen S, Kekalainen E, Ahava MJ, Loginov R, Kallio-Kokko H, et al.
449	Performance of six SARS-CoV-2 immunoassays in comparison with microneutralisation. J Clin
450	Virol. 2020;129:104512.
451	14. Laboratories A. AdviseDx SARS-CoV-2 lgG 2021 [Available from:
452	https://www.fda.gov/media/146371/download.
453	15. Harris PA, Taylor R, Thielke R, Payne J, Gonzalez N, Conde JG. Research electronic data
454	capture (REDCap)a metadata-driven methodology and workflow process for providing
455	translational research informatics support. J Biomed Inform. 2009;42(2):377-81.

456 Harris PA, Taylor R, Minor BL, Elliott V, Fernandez M, O'Neal L, et al. The REDCap 16. 457 consortium: Building an international community of software platform partners. J Biomed 458 Inform. 2019;95:103208. 459 17. Wang Y, Zhang L, Sang L, Ye F, Ruan S, Zhong B, et al. Kinetics of viral load and antibody 460 response in relation to COVID-19 severity. J Clin Invest. 2020;130(10):5235-44. 461 Ravichandran S, Lee Y, Grubbs G, Coyle EM, Klenow L, Akasaka O, et al. Longitudinal 18. 462 antibody repertoire in "mild" versus "severe" COVID-19 patients reveals immune markers 463 associated with disease severity and resolution. Sci Adv. 2021;7(10). 464 19. Ibarrondo FJ, Fulcher JA, Goodman-Meza D, Elliott J, Hofmann C, Hausner MA, et al. 465 Rapid Decay of Anti-SARS-CoV-2 Antibodies in Persons with Mild Covid-19. N Engl J Med. 466 2020;383(11):1085-7. 467 20. Self WH, Tenforde MW, Stubblefield WB, Feldstein LR, Steingrub JS, Shapiro NI, et al. 468 Seroprevalence of SARS-CoV-2 Among Frontline Health Care Personnel in a Multistate Hospital 469 Network - 13 Academic Medical Centers, April-June 2020. MMWR Morb Mortal Wkly Rep. 470 2020;69(35):1221-6. 471 Bruno-Murtha LA, Osgood R, Lan FY, Buley J, Nathan N, Weiss M, et al. SARS-CoV-2 21. 472 antibody seroprevalence after the first wave among workers at a community healthcare system 473 in the Greater Boston area. Pathog Glob Health. 2021:1-4. 474 Fenwick C, Croxatto A, Coste AT, Pojer F, Andre C, Pellaton C, et al. Changes in SARS-22. 475 CoV-2 Spike versus Nucleoprotein Antibody Responses Impact the Estimates of Infections in 476 Population-Based Seroprevalence Studies. J Virol. 2021;95(3). 477 Harris RJ, Hall JA, Zaidi A, Andrews NJ, Dunbar JK, Dabrera G. Effect of Vaccination on 23. 478 Household Transmission of SARS-CoV-2 in England. N Engl J Med. 2021;385(8):759-60. 479 24. Mostaghimi D, Valdez CN, Larson HT, Kalinich CC, Iwasaki A. Prevention of host-to-host 480 transmission by SARS-CoV-2 vaccines. Lancet Infect Dis. 2021. 481 Po Ying Chia SWXO, Calvin J Chiew, Li Wei Ang, Jean-Marc Chavatte, Tze-Minn Mak, Lin 25. 482 Cui, Shirin Kalimuddin, Wan Ni Chia, Chee Wah Tan, Louis Yi Ann Chai, Seow Yen Tan, Shuwei 483 Zheng, Raymond Tzer Pin Lin, Linfa Wang, Yee-Sin Leo, Vernon J Lee, David Chien Lye, Barnaby 484 Edward Young. Virological and serological kinetics of SARS-CoV-2 Delta variant vaccine-485 breakthrough infections: a multi-center cohort study. MEDRxiv. 2021. 486 Tahamtan A, Ardebili A. Real-time RT-PCR in COVID-19 detection: issues affecting the 26. 487 results. Expert Rev Mol Diagn. 2020;20(5):453-4. 488 Kim JY, Ko JH, Kim Y, Kim YJ, Kim JM, Chung YS, et al. Viral Load Kinetics of SARS-CoV-2 27. 489 Infection in First Two Patients in Korea. J Korean Med Sci. 2020;35(7):e86. 490 28. Public Health England PD, Nuffield Department of Medicine UoO, Trust OUHNF. 491 Evaluation of sensitivity and 492 specificity of four commercially 493 available SARS-CoV-2 antibody 494 immunoassays. Public Health England. 2020. 495 Kim Y, Lee JH, Ko GY, Ryu JH, Jang JH, Bae H, et al. Quantitative SARS-CoV-2 Spike 29. 496 Antibody Response in COVID-19 Patients Using Three Fully Automated Immunoassays and a 497 Surrogate Virus Neutralization Test. Diagnostics (Basel). 2021;11(8).

- 498 30. Ekelund O, Ekblom K, Somajo S, Pattison-Granberg J, Olsson K, Petersson A. High-
- throughput immunoassays for SARS-CoV-2 considerable differences in performance when
 comparing three methods. Infect Dis (Lond). 2021;53(10):805-10.
- 501 31. Kahn R, Kennedy-Shaffer L, Grad YH, Robins JM, Lipsitch M. Potential biases arising from
- 502 epidemic dynamics in observational seroprotection studies. medRxiv. 2020.

- 506 Legend:
- 507 Figure 1 Linearity of Anti-S IgG
- **Table 1** Population Demographics by Anti-S IgG quant
- 509 Figure 2 Anti-S IgG by demographics a). Age b). Gender c). Race
- **Table 2** Anti-S IgG vs. SARS-CoV-2 RT-PCR
- **Figure 3** Anti-S IgG distribution by SARS-CoV-2 RT-PCR status
- 512 Figure 4 Anti-S IgG distribution days post SARS-CoV-2 RT-PCR result
- 513 Table 3 Anti-N IgG vs. Anti-S IgG Agreement









	A	Anti-S IgG Status			
Variable	Total n (column %)	Positive n (row %)	Negative n (row %)	p-value (All Data)	RR (95% CI) (All Data)
Total	1743 (100.00)	126 (7.23)	1617 (92.77)		
Sex				0.31	
Female	1306 (74.93)	102 (7.81)	1204 (92.19)		Referent
Male	431 (24.73)	24 (5.57)	407 (94.43)		0.71 (0.46, 1.10
Nonbinary/3rd Gender	3 (0.17)	0 (0.00)	3 (100.00)		0.00 (N/A)**
Average Age (years) (SD)	41.16 (12.39)	41.00 (12.21)	41.17 (12.41)	0.53	
BMI				p < 0.001*	
Underweight (<18.5 kg/m²)	34 (1.95)	0 (0.00)	34 (100.00)		0.00 (N/A)**
Normal (18.5-24.9 kg/m ²)	844 (48.42)	53 (6.28)	791 (93.72)		Referent
Overweight (25.0-29.9 kg/m ²)	528 (30.29)	29 (5.49)	499 (94.51)		0.87 (0.56, 1.36
Obese (>29.9 kg/m ²)	335 (19.22)	43 (12.84)	292 (87.16)		2.04 (1.40, 2.99
Hispanic/LatinX				0.10	
Yes	143 (8.20)	15 (10.49)	128 (89.51)		Referent
No	1594 (91.45)	109 (6.84)	1485 (93.16)		0.65 (0.39, 1.09
Race				0.52	
White	1299 (74.53)	87 (6.70)	1212 (93.30)		Referent
Asian	160 (9.18)	10 (6.25)	150 (93.75)		0.93 (0.50, 1.76
Black	141 (8.09)	13 (9.22)	128 (90.78)		1.38 (0.79, 2.40
Native American / Pacific Islander	7 (0.40)	0 (0.00)	7 (100.00)		0.00 (N/A)**
Other	123 (7.06)	12 (9.76)	111 (90.24)		1.46 (0.82, 2.59
Smoking				0.77	
No	1671 (95.87)	122 (7.30)	1549 (92.70)		Referent
Yes	46 (2.64)	4 (8.70)	42 (91.30)		1.19 (0.46, 3.09

Table 1 - Population Demographics by Anti-S IgG quant

* Statistically significant when p-value < 0.05 **N/A: unable to divide by 0

Column percentages may not always add up to 100% due to missing data of <5.0%





Table 2 – Anti-S IgG vs. SARS-CoV-2 RT-PCR

			SARS-CoV	-2 RT-PCR	
		Positive	Negative	IND*	Not Tested
Anti S IgC	+	75	9	2	40
Anti-S IgG	-	10	341	4	1262

*Indeterminate











b.





a.

		Anti-S IgG	
273		+	
	+	89	6
Anti-N IgG	-	37	1611

McNemar's Test Statistic with Yates' Continuity Correction: 20.93 P value: <0.0001

		Anti-S IgG	
		+	-
Anti-N IgG	+	109	21
	-	17	1596

McNemar's Test Statistic with Yates' Continuity Correction: 0.24 P value: <0.0001